Form 1 Interview Guide

OMB Number: 0925-0046

Expiration Date: 05/31/2016

Attachment 1: Interviews with Stakeholders of National Cancer Institute’s (NCI) Mouse Models of Human Cancers Consortium (NCI-MMHCC)

Burden Statement

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0046). Do not return the completed form to this address.

Introduction

Thank you for consenting to participate in this interview to expose the opportunities and challenges for the use of mouse models in cancer research. As you are aware, the National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium is conducting this interview to obtain information on the degree of awareness of the mouse and human-in-mouse models that support basic, translational, clinical, and epidemiological research applications, how satisfied you are with these resources, and how we can improve and promote the program and communication among the various stakeholders in the cancer research community. Do you have any questions about the information that you have received regarding this stakeholder satisfaction interview?

Overview of the Process

This interview will last approximately 30 minutes. The information and opinions that you provide will be used to determine how the cancer research community develops and uses mice and mouse models, the evolution of standard practices in the development and use of mouse models, and future directions in these areas. The information that you provide will be kept secure to the extent provided by law; we will not attribute quotes or specific perspectives to you. Your responses will be audio-recorded to ensure that your comments are captured accurately. The audio files will be deleted following the interview.

Interview Questions

1. Please indicate your title and role in your organization.

2. In what capacity do you use mouse or human-in-mouse models or data generated from them in your work?

3. From your perspective as a [academic basic, translational, clinical, epidemiological, private sector] researcher, what research questions need to be addressed using translational mouse models (e.g., type of cancer, specific signaling pathways)?

4. Please describe any emerging opportunities for fully integrating mouse models or data from mouse models in [academic basic, translational, clinical, epidemiological, private sector] research applications (e.g., cutting-edge human-in-mouse experiments, computational methods).

5. What current challenges exist to fully integrating mouse models in [academic basic, translational, clinical, epidemiological, private sector] research applications, and how can these challenges be addressed (e.g., technology needs, supporting infrastructure, databases)?

6. What capacity, knowledge, and skills does the [academic basic, translational, clinical, epidemiological, private sector] research community need to develop to make the best use of mouse models as translational research tools (e.g., improved study design, training, statistical analyses)?

7. What collaborations can be developed to foster best practices for pre-, co-, and post-clinical applications of mouse models (e.g., public-private partnerships, opportunities to share data)?

Follow-Up

Following the conclusion of the interviews, the NCI Oncology Models Forum will conduct focus groups based on the analysis of interview responses to better understand the specific needs of academic basic, translational, clinical, epidemiological, and private sector researchers. Please let us know if you would be interested in participating in a focus group in the Spring of 2014¹.

1 If focus groups are planned, a separate PRA/OMB clearance will be requested to conduct these.

1